-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Seaport Therapeutics, Raises Price Target to $41

Benzinga·11/05/2026 23:42:20
Listen to the news
JP Morgan analyst Tessa Romero maintains Seaport Therapeutics (NASDAQ:SPTX) with a Overweight and raises the price target from $40 to $41.